Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 43, 2013 - Issue 3
241
Views
1
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Disposition and metabolism of [14C]PTZ601 in healthy volunteers

, , , , , , & show all
Pages 283-292 | Received 29 May 2012, Accepted 23 Jul 2012, Published online: 29 Aug 2012

References

  • Cirillo I, Mannens G, Janssen C, Vermeir M, Cuyckens F, Desai-Krieger D, Vaccaro N,Kao LM, Devineni D, Redman R, Turner K. (2008). Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother 52:3478–3483. Epub 2008 Jul 21.
  • Harrison MP, Haworth SJ, Moss SR, Wilkinson DM, Featherstone A. (1993). The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 23:1311–1323.
  • Kihara R, Yanagihara K, Morinaga Y, Araki N, Nakamura S, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Tsukamoto K, Kamihira S, Kohno S. (2008). Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 52:2163–2168.
  • King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. (2006). Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144:309–317.
  • Livermore DM, Mushtaq S, Warner M. (2009). Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 64:330–335.
  • Livermore DM, Warner M. (2009). Effects of low temperature and high salt on the activity of the novel carbapenem PZ-601 (SMP-601) against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 63:411–413.
  • MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K. (2011). Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:1436–1442.
  • Norrby SR, Björnegård B, Ferber F, Jones KH. (1983). Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 12 Suppl D: 109–124.
  • Norrby SR, Rogers JD, Ferber F, Jones KH, Zacchei AG, Weidner LL, Demetriades JL, Gravallese DA, Hsieh JY. (1984). Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother 26:707–714.
  • Rhee KY, Gardiner DF, Charles M. (2005). Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis 40:1705–1706.
  • Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC; Infectious Diseases Society of America. (2005). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41:1373–1406.
  • Tran CM, Tanaka K, Yamagishi Y, Goto T, Mikamo H, Watanabe K. (2011). In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrob Agents Chemother 55:2398–2402.
  • Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. (2005). In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 49:4185–4196.
  • Young C, Rusca A, Di Stefano A, Radicioni M, Binelli D, Xerri L. (2007). Safety and pharmacokinetics of single-dose intravenous administration of PZ-601: a novel investigational carbapenem. Int J Antimicrob Agents 29:S473–S474.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.